BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

T ISOZAKI; M KIMURA; N IKEGAYA; T ARAI; Y FUJIGAKI; A HISHIDA; E KANEKO

BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

T ISOZAKI
, M KIMURA
, N IKEGAYA
, T ARAI
, Y FUJIGAKI
, A HISHIDA
, E KANEKO

医学部

研究成果: ジャーナルへの寄稿 › 記事

抄録

Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.

本文言語	英語
ページ（範囲）	1036-1042
ページ数	7
ジャーナル	Clinical Investigator
巻	70
号	11
出版ステータス	出版済み - 11月 1992

フィンガープリント

「BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{fc8391db96674cf2bd1a90bd87493b7c,

title = "BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE",

abstract = "Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.",

author = "T ISOZAKI and M KIMURA and N IKEGAYA and T ARAI and Y FUJIGAKI and A HISHIDA and E KANEKO",

year = "1992",

month = nov,

language = "英語",

volume = "70",

pages = "1036--1042",

journal = "Clinical Investigator",

issn = "0941-0198",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

TY - JOUR

T1 - BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

AU - ISOZAKI, T

AU - KIMURA, M

AU - IKEGAYA, N

AU - ARAI, T

AU - FUJIGAKI, Y

AU - HISHIDA, A

AU - KANEKO, E

PY - 1992/11

Y1 - 1992/11

N2 - Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.

AB - Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.

M3 - 記事

SN - 0941-0198

VL - 70

SP - 1036

EP - 1042

JO - Clinical Investigator

JF - Clinical Investigator

IS - 11

ER -